Exercise-induced bronchoconstriction

Summary

Exercise-induced bronchoconstriction (MONDO:0850286) is a disease and 10 clinical trials. Top therapeutic interventions include albuterol and cromolyn sodium. A subtype of intrinsic asthma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	exercise-induced bronchoconstriction
Mondo ID	MONDO:0850286
DOID	DOID:0080821
UMLS	C0015263
MedGen	4606
Is cancer (heuristic)	no

Disease family

This is a subtype of intrinsic asthma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › bronchial disorder › asthma › intrinsic asthma › exercise-induced bronchoconstriction

Related subtypes (2): environmental induced asthma, aspirin-induced respiratory disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00534976	PHASE4	COMPLETED	The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
NCT01791972	PHASE3	COMPLETED	Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
NCT04408664	PHASE3	TERMINATED	Influence of Cromones on Eucapnic Hyperventilation (EVH)-Test in Young (Elite) Athletes Who Tested Positive for EIB.
NCT06480084	Not specified	NOT_YET_RECRUITING	Prevalence of EILO Among Children With Asthma
NCT01214551	Not specified	COMPLETED	Exercise-induced Bronchoconstriction Diagnostics: Impact of a Repeated Exercise Challenge Test
NCT01504646	Not specified	COMPLETED	Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma
NCT02252302	Not specified	COMPLETED	Exercise in Air Pollution and Lung Health in Asthmatics
NCT04103632	Not specified	COMPLETED	Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y)
NCT04275648	Not specified	COMPLETED	Exercise Induced Bronchoconstriction and Field Tests
NCT07466849	Not specified	COMPLETED	Hypoxic Environment on EIB and Performance in Race Walkers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALBUTEROL	4	2
CROMOLYN SODIUM	4	1